Lipella

Lipella Pharmaceuticals Inc. is a privately held development-stage biotechnology company dedicated to improve patient care by developing novel products.

[Lipella @LipellaPharma]

.@LipellaPharma $LIPO Pharmaceuticals has announced the renewal of its manufacturing collaboration agreement with Cook MyoSite, Inc. This CMC collaboration is increasingly valuable to Lipella as the clinical pipeline matures toward commercializing assets. Read more here: https://t.co/GTOxx9wONq

[Lipella @LipellaPharma]

.@LipellaPharma is proud to present Phase 2a data for LP-310 in Oral Lichen Planus at the 2025 AAOM/EAOM International Meeting. The topline
results from the 0.25 mg and 0.50 mg dose cohorts highlight statistically significant safety and efficacy outcomes in this underserved indication.
$LIPO
 https://t.co/Cn96CJkTBd

[Lipella @LipellaPharma]

We are pleased to announce that our LP-10 abstract on oral lichen planus has been accepted for podium presentation at the 2025 AAOM/EAOM International Meeting in Las Vegas. The presentation will be delivered by Dr. Alessandro Villa of Miami Cancer Institute, a member of Lipella’s Oral Lichen Planus Advisory Board. https://t.co/arc4xgBf99
#stockstowatch #stocksinnews #investors #daytrader
#LIPO

[Lipella @LipellaPharma]

Lipella announces additional positive Phase 2a data for LP-310 in oral lichen planus. The 0.50 mg cohort showed statistically significant improvements across key clinical measures with no treatment-related serious adverse events. Final results from the 1.0 mg cohort expected Q2 2025. https://t.co/arc4xgBf99
#stockstowatch #stocksinnews #investors #LIPO

[Lipella @LipellaPharma]

.@LipellaPharma $LIPO recent Phase 2a Trial news was featured by Clinical Trials Arena. Read more here: https://t.co/s5OVBnI8u8
#stockstowatch #stocksinnews #investors #smallcaps

[Lipella @LipellaPharma]

IN CASE YOU MISSED IT: Our co-founder Michael Chancellor was featured on the Pharmaverse Podcast where he provides insights into his work with @LipellaPharma and leadership advice to those in the field.
#stockstowatch #stocksinnews #investors #smallcaps
https://t.co/YqcdyRd2gK

[Lipella @LipellaPharma]

.@LipellaPharma $LIPO is pleased to announce the completion of patient enrollment for its Phase 2a study of LP-310 for Oral Lichen Planus. Topline results are expected in Q2 2025. With the final cohort now fully enrolled we are eager to share the data and shape our next steps. Read more here: Lipella Pharmaceuticals Completes Enrollment in Phase 2a
#stockstowatch #stocksinnews #investors #smallcaps

[Lipella @LipellaPharma]

.@LipellaPharma $LIPO is pleased to announce significant Phase 2a Topline Data for LP-310, our liposomal-tacrolimus oral rinse formulation of LP-10, to treat oral lichen planus (OLP). LP-310 demonstrated clinically meaningful reductions in pain, ulceration, and inflammation across all key metrics. Read more here:
https://t.co/U71c6me3oL
#LIPO #toplinedata #LP310 #OLP

[Lipella @LipellaPharma]

.@LipellaPharma is pleased to announce the FDA has granted approval for Expanded Access Program for LP-310 in Oral Lichen Planus (OLP). This program will allow OLP patients to access treatments outside of a clinical trial that are not yet approved by the FDA and reinforces LP-310’s potential as a new therapeutic option for OLP, supporting ongoing clinical development efforts. Read more here: https://t.co/ndO7UURkAc
#LIPO #LP310 #orallichenplanus #FDA #EAP

[Lipella @LipellaPharma]

.@LipellaPharma (Nasdaq: $LIPO) has announced a publication in @CureusMedical, a peer-reviewed article highlighting the potential treatment for Oral Lichen Planus (OLP) with a focus on localized drug delivery. The paper emphasizes the potential of Lipella’s investigational therapy, LP-310, a novel oral rinse formulation of LP-10 (tacrolimus) specifically designed to provide localized therapeutic effects for OLP while minimizing systemic exposure. Read more here: https://t.co/lA5QQOP10K #LIPO #OLP #peerreview #CUREUS #LP310 #LP10

[Lipella @LipellaPharma]

Today $LIPO has announced the completion of dosing for the first cohort in our multi-center Phase 2a clinical trial of LP-310, a liposomal-tacrolimus oral rinse being developed for the treatment of Oral Lichen Planus (OLP). The pace of our promising progress puts us on track to deliver top-line data by year-end and complete the trial by mid-2025. Read the full release here: https://t.co/6nqZA81bTF
#LIPO #clinicaltrials #Phase2a #OLP

[Lipella @LipellaPharma]

Our recent patent news has been featured by @BioTuesdays . “We believe our proprietary liposomal delivery platform holds significant potential to enhance efficacy and tolerability across various therapeutic areas, including oncology, cancer survivorship and immunotherapy,” stated @LipellaPharma $LIPO ’ Chief Medical Officer, Michael Chancellor. Read the full BioTuesday report here:  https://t.co/iJPlORgZDM
#LIPO #patents #recentnews #liposome #biotuesdays

[Lipella @LipellaPharma]

We are pleased to announce we will be attending the 2024 Spartan Capital Investor Conference in New York that will be held on November 4th, 2024. @LipellaPharma $LIPO CEO Jonathan Kaufman will be presenting at 9:25am EST and is available for one-on-one meetings with registered investors of the conference. #LIPO #spartancapital #investorconference #presentation

[Lipella @LipellaPharma]

.@LipellaPharma $LIPO has received a notice of allowance from the U.S. Patent and Trademark Office (USPTO) for its proprietary liposomal drug delivery platform. Read more here: https://t.co/PLmnM1k8QT #LIPO #patent #IPprotection #liposomes #drugdelivery

[Lipella @LipellaPharma]

This month we will be attending the 2024 Maxim Healthcare Virtual Summit. Lipella $LIPO CEO Jonathan Kaufman will be presenting on Thursday, October 17 that 10:30am. Tune in to the live webcast here: https://t.co/tMXRbZrHxw #LIPO #MaximConference #presentation #OLP #investors